vs
Side-by-side financial comparison of AGIOS PHARMACEUTICALS, INC. (AGIO) and Sanofi (SNY), based on the latest 10-Q / 10-K filings. Click either name above to swap in a different company.
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company trades as "SAN" on Euronext Paris and "SNY" on Nasdaq in the United States, and is a component of th...
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history — bar widths are scaled to the larger of the two companies so you can eyeball the size gap and growth trajectory without doing math. Quarters aligned by calendar period (report date) so offset fiscal years line up.
| Q4 25 | $20.0M | — | ||
| Q3 25 | $12.9M | — | ||
| Q2 25 | $12.5M | — | ||
| Q1 25 | $8.7M | — | ||
| Q4 24 | $10.7M | — | ||
| Q3 24 | $9.0M | — | ||
| Q2 24 | $8.6M | — | ||
| Q1 24 | $8.2M | — |
| Q4 25 | $-108.0M | — | ||
| Q3 25 | $-103.4M | — | ||
| Q2 25 | $-112.0M | — | ||
| Q1 25 | $-89.3M | — | ||
| Q4 24 | $-96.5M | — | ||
| Q3 24 | $947.9M | — | ||
| Q2 24 | $-96.1M | — | ||
| Q1 24 | $-81.5M | — |
| Q4 25 | 90.6% | — | ||
| Q3 25 | 87.0% | — | ||
| Q2 25 | 86.3% | — | ||
| Q1 25 | 87.6% | — | ||
| Q4 24 | 88.3% | — | ||
| Q3 24 | 91.3% | — | ||
| Q2 24 | 82.6% | — | ||
| Q1 24 | 92.3% | — |
| Q4 25 | -608.9% | — | ||
| Q3 25 | -907.4% | — | ||
| Q2 25 | -1020.1% | — | ||
| Q1 25 | -1222.0% | — | ||
| Q4 24 | -1165.3% | — | ||
| Q3 24 | -1146.9% | — | ||
| Q2 24 | -1228.3% | — | ||
| Q1 24 | -1124.3% | — |
| Q4 25 | -541.1% | — | ||
| Q3 25 | -803.1% | — | ||
| Q2 25 | -899.4% | — | ||
| Q1 25 | -1023.3% | — | ||
| Q4 24 | -899.6% | — | ||
| Q3 24 | 10574.7% | — | ||
| Q2 24 | -1115.7% | — | ||
| Q1 24 | -995.8% | — |
| Q4 25 | $-1.86 | — | ||
| Q3 25 | $-1.78 | — | ||
| Q2 25 | $-1.93 | — | ||
| Q1 25 | $-1.55 | — | ||
| Q4 24 | $-1.44 | — | ||
| Q3 24 | $16.22 | — | ||
| Q2 24 | $-1.69 | — | ||
| Q1 24 | $-1.45 | — |
Financial Flow Comparison
Sankey diagram of revenue → gross profit → operating profit → net profit for each company. Charts shown full-width and stacked so both segment hierarchies are readable side-by-side on desktop and mobile.
